SCHEMBL4823799

SCHEMBL4823799

CC1COCCN1C(=O)OC1CCCN(c2ccc(F)cc2F)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 4/20 0.41
CDK2 P24941 4/20 0.41
GSK3B P49841 3/20 0.41
ACACB O00763 2/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
KDM4E B2RXH2 2/20 0.38
HTT P42858 1/20 0.38
PIK3C3 Q8NEB9 2/20 0.38
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
CHRM4 P08173 1/20 0.37
HCRTR2 O43614 1/20 0.36
CNR1 P21554 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
WDR5 P61964 1/20 0.36
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4756496 0.91 MAPT (0.42) CCNE1CDK2GSK3BACACBMAPT
SCHEMBL4759277 0.79 ACACB (0.45) ACACBMAPTALDH1A1KDM4EHTT
SCHEMBL4757473 0.77 ACACB (0.44) ACACBALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL14437329 0.77 ACACB (0.42) ACACBLMNAALDH1A1KDM4EHTT
SCHEMBL31512366 0.76 CA12 (0.45) CCNE1CDK2GSK3BPIK3C3
SCHEMBL14436814 0.75 ACACB (0.41) ACACBALDH1A1KDM4EHTTCNR1
SCHEMBL5661789 0.75 ACACB (0.41) ACACBALDH1A1KDM4EHTTCNR1
SCHEMBL4707591 0.74 ACACB (0.41) ACACBALDH1A1KDM4EHTT
SCHEMBL5661324 0.73 ACACB (0.41) ACACBKDM4EHTTSMN1; SMN2
SCHEMBL14441581 0.71 ACACB (0.43) ACACBMAPTKDM4EHTTCHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US claimed
EP-1979318-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-10-15 EP disclosed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO disclosed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197530-A1 Amido compounds and their use as pharmaceuticals HSD11B1, HSD17B11, CYP11B1 CCNE1 3577/4885CDK2 3965/4885GSK3B 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.